Skip to main content
main-content
Top

03-17-2019 | Canagliflozin | News

ACC in brief

Canagliflozin may reduce HF events irrespective of ejection fraction

medwireNews: A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure (HF) events regardless of whether patients have preserved or reduced ejection fraction.

“This may provide some hope for patients with diabetes and HF [with preserved ejection fraction], where no prior intervention has been shown to have clear clinical benefits,” write Gemma Figtree (Royal North Shore Hospital, Sydney, New South Wales, Australia) and study co-authors in Circulation.

Over an average follow-up of 3.6 years, 101 of the total 10,142 CANVAS participants died or were hospitalized due to HF with preserved ejection fraction, 122 with reduced ejection fraction, and 61 with unknown ejection fraction.

Canagliflozin versus placebo reduced the risk for HF events by 31% for reduced ejection fraction, 17% for preserved ejection fraction, and 46% for unknown ejection fraction.

The researchers say there are “no clear differences” in the effects of canagliflozin between the three groups, but stress that they had no knowledge of patients’ ejection fractions prior to the HF event, and so “additional data from dedicated HF [with preserved ejection fraction] trials are required.”

The findings were also presented at the American College of Cardiology 68th Annual Scientific Session in New Orleans, Louisiana.

By Eleanor McDermid

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

Related topics